BioXcel Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
4analysts covering
FY Revenue (est.)
$769.9Knext fiscal year
FY EPS (est.)
-$2.62next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| FDA PDUFA Target Action Date for IGALMI sNDA | 14 Nov 2026 |
Monitoring Framework
Key Performance Indicators
IGALMI Net Product Revenue Quarterly206KTarget: Significant commercial scale-up post at-home approval
Cash and Cash Equivalents Balance Quarterly17.2MTarget: Sufficient capital to resolve going concern status
Quarterly Net Loss Quarterly12.7MTarget: Reduction in cash burn through clinical prioritization
Watch Items
- FDA sNDA Decision for IGALMI At-Home UseTrigger: PDUFA Target Action Date: November 14, 2026Action: Monitor FDA announcements and prepare commercial launch infrastructure if approved.
- Going Concern Status and Strategic Alternatives EvaluationTrigger: Cash runway projected into Q2 2026 (exhaustion imminent without capital)Action: Track progress of MTS Health Partners' evaluation of strategic options (sale, merger, or partnership).
- Nasdaq Listing ComplianceTrigger: Stock price trading near $1.00 to $1.20Action: Monitor for minimum bid price deficiency notices and potential reverse stock split plans.
Research as of 19 Jun 2026